Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Clinical and Radiographic Outcomes of Lesion Sterilization and Tissue Repair Using Zinc Oxide/ 6-gingerol Mix Versus Triple Antibiotic Paste in Non-vital Primary Molars

NCT07488416 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2026-03-23

Condition(s) studied

Clinical OutcomesRadiographic OutcomesLesion SterilizationTissue RepairZinc Oxide6-gingerolTriple Antibiotic PasteNon-vitalPrimary Molars

Investigational drug(s) / intervention(s)

Zinc oxide/ 6-gingerol mixTriple antibiotic paste

Zinc oxide/ 6-gingerol mix: Lesion sterilization and tissue repair (LSTR) using zinc oxide/ 6-gingerol mix.

Triple antibiotic paste: Lesion sterilization and tissue repair (LSTR) using triple antibiotic paste.

Study summary

This study aims to evaluate and compare the clinical and radiographic outcomes of Lesion sterilization and tissue repair using zinc oxide/ 6-gingerol mix versus triple antibiotic paste in non-vital primary molars.

Eligibility

Sex
ALL
Min age
4 Years
Max age
8 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 4 to 8 years. * Both sexes * Children must have at least two restorable non-vital primary molars * Periapical radiolucency. * Pain on mastication. * Pathological mobility. * Internal or external root resorption. * Furcation involvement should not extend to the developing tooth germ. Exclusion Criteria: * Presence of systemic diseases. * Teeth with physiological mobility near exfoliation time. * Teeth with vital pulp.

Primary outcome measure(s)

  • Assessment of pain — 6 months postoperatively
    Pain will be assessed using age-appropriate pain scales (5-point Likert scale for children) with 0 typically representing "no pain" and 4 representing "very high/extreme pain".

Trial sites (1)

FacilityCityRegionStatus
Al-Azhar University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07488416 on ClinicalTrials.gov ↗ ← All trials in Egypt